Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Julphar
Fish and Richardson
Federal Trade Commission
Citi

Generated: June 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,921,528

« Back to Dashboard

Which drugs does patent 6,921,528 protect, and when does it expire?

Patent 6,921,528 protects INBRIJA and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.

Summary for Patent: 6,921,528
Title: Highly efficient delivery of a large therapeutic mass aerosol
Abstract:A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm.sup.3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g/cm.sup.3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm.sup.3.
Inventor(s): Edwards; David A. (Boston, MA), Batvcky; Richard P. (Auburndale, MA), Johnston; Lloyd (Belmont, MA)
Assignee: Advanced Inhalation Research, Inc. (Cambridge, MA)
Application Number:10/681,416
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,921,528
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 6,921,528

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Daiichi Sankyo
Teva
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.